AcuraStem, founded in 2016, is a patient-based biotechnology company focused on developing innovative treatments for neurodegenerative diseases, particularly sporadic ALS and FTD. The company's core mission revolves around its proprietary disease-modeling platform, iNeuroRx®, which aims to revolutionize drug discovery for these conditions. AcuraStem's approach emphasizes patient-focused research to overcome the limitations of traditional animal models in drug development.
The company's iNeuroRx® platform is recognized as a best-in-class tool for discovering novel, effective, and broadly-acting treatments. AcuraStem's work addresses a critical gap in the pharmaceutical industry, where drug failures in clinical trials often stem from an overreliance on animal models. By prioritizing patient-based research, AcuraStem strives to improve the understanding of neurodegenerative diseases and increase the success rate of drug development in this challenging field.
